Cadila Healthcare Limited has entered into a definitive agreement with Shilpa Medicare Limited, a contract manufacturing organization to produce mutually agreeable doses of ZyCoV-D. The company also entered into an agreement with Enzychem Lifesciences of Republic of Korea for the manufacturing license and technology transfer for the Plasmid DNA Vaccine.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
569.6 INR | +1.61% |
|
-1.68% | +72.38% |
06-25 | Shilpa Medicare Bio Analytical Unit Gets "No Action Indicated" Classification from US FDA | MT |
05-24 | Transcript : Shilpa Medicare Limited, Q4 2024 Earnings Call, May 24, 2024 |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
1,967 KRW | -2.38% | +0.10% | 121M | ||
1,074 INR | +1.60% | -1.02% | 12.96B | ||
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+72.38% | 593M | |
+55.32% | 815B | |
+44.05% | 641B | |
-6.75% | 352B | |
+13.56% | 314B | |
+10.68% | 303B | |
+16.57% | 242B | |
+13.31% | 218B | |
+8.48% | 168B | |
-2.81% | 159B |
- Stock Market
- Equities
- SHILPAMED Stock
- News Shilpa Medicare Limited
- Cadila Healthcare Limited Entered into A Definitive Agreement with Shilpa Medicare Limited and Enzychem Lifesciences